Differences

This shows you the differences between two versions of the page.

--- michael_callahan [2023/03/02 19:25]
liam
+++ michael_callahan [2023/07/05 21:14] (current)
liam
@@ Line 4: / Line 4: @@
 Dr. **Michael Callahan** is an American infectious diseases scientist. He is a staff physician at the [[Massachusetts General Hospital]] (MGH) and a clinical subject matter expert for international clinical trials for the [[Assistant Secretary of Public Health Preparedness]] (ASPR) of the [[United States Department of Health and Human Services ]] (HHS).((//Michael Callahan.// Vaccine & Immunotherapy Center. Retrieved March 2, 2023, from https://web.archive.org/web/20230302083941/https://advancingcures.org/vic-management-michael-callahan/))
+He also maintains appointments at [[Harvard Medical School]] and [[King Chulalongkom Medical University]] in Bangkok, and consults for the [[National Academies of Sciences, Engineering and Medicine]], [[National Security Council]] (NSC), [[Biological Sciences Experts Group]] (BSEG), the [[Office of Net Assessment]] (ONA), [[National Institute of Allergy and Infectious Diseases]] (NIAID), [[Mitre]], the [[American Society of Microbiology]], [[Infectious Diseases Society of America]] (IDSA), and the [[American Society of Tropical Medicine and Hygiene]].
+Callahan serves as President of Cellular Therapies at [[pharmaceutical_companies:United Therapeutics Corporation]].
 ===== History =====
@@ Line 13: / Line 17: @@
 ==== Career ====
-In 2002, Callahan was appointed clinical director for [[Office of Cooperative Threat Reduction|Cooperative Threat Reduction]] programs at six former [[Soviet Union]] biological weapons institutes (including [[Vector Institute]], [[State Research Center for Applied Microbiology]], [[Scientific Research Institute of Microbiology]] and [[Research Center of Molecular Diagnostics & Therapy]]), which included redirecting of unanticipated dual use and [[gain-of-function]] programs.
+In 2002, Callahan was appointed clinical director for [[Office of Cooperative Threat Reduction|Cooperative Threat Reduction]] programs at six former [[Soviet Union]] biological weapons institutes (including [[State Research Center of Virology and Biotechnology VECTOR]], [[State Research Center for Applied Microbiology]], [[Scientific Research Institute of Microbiology]] and [[Research Center of Molecular Diagnostics & Therapy]]), which included redirecting of unanticipated dual use and [[gain-of-function]] programs.
 === DARPA ===
-Callahan was recruited in 2004 by the [[Defense Advanced Research Projects Agency]] (DARPA) to run their $260M Accelerated Manufacture of Pharmaceuticals program dealing with pandemics and microbial resistance.((//Michael Callahan.// Vaccine & Immunotherapy Center. Retrieved March 2, 2023, from https://web.archive.org/web/20230302083941/https://advancingcures.org/vic-management-michael-callahan/))
+Callahan was recruited in 2004 by the [[Defense Advanced Research Projects Agency]] (DARPA) to run their $260M Accelerated Manufacture of Pharmaceuticals program dealing with pandemics and microbial resistance.((//Michael Callahan.// Vaccine & Immunotherapy Center. Retrieved March 2, 2023, from https://web.archive.org/web/20230302083941/https://advancingcures.org/vic-management-michael-callahan/)) He ran the program from 2005-2012.
-While at DARPA, he launched the [[Accelerated Manufacture of Pharmaceuticals]] (AMP) program, for which he received the 2010 DARPA Achievement Award, and which generated emergency use good manufacturing practice [[pH1N1 vaccines]], and [[Nicotinia]]-expressed [[monoclonal antibodies|monoclonals]] such as [[ZMapp]].
+While at DARPA, he launched the [[Accelerated Manufacture of Pharmaceuticals]] (AMP) program, for which he received the 2010 DARPA Achievement Award, and which generated emergency use good manufacturing practice [[pH1N1 vaccines]], and [[Nicotinia]]-expressed [[monoclonal antibodies|monoclonals]] such as [[ZMapp]]. Also while at DARPA, he launched [[Prophecy]], an international physician "early alert" network which delivers 24/7 emergency consultation, reagents and therapeutics for catastrophic infectious disease outbreaks.
 === Zika ===
@@ Line 32: / Line 36: @@
 ----
- From 2005 to 2012,
-Dr. Callahan led the Defense Advanced Research Projects Agency [[DARPA]] biodefense [[therapeutics portfolio]], which he expanded from $61 million to $260 million per annum in 2011, involving eight programs that generated nine investigational new drugs (INDs) and three new drug applications with products in market.
-While at DARPA he launched the Department of Defense Icon program Accelerated Manufacture of Pharmaceuticals (AMP), for which he received the 2010 DARPA Achievement Award, and which generated emergency use good manufacturing practice [[pH1N1 vaccines]], and [[Nicotinia-expressed monoclonals]] such as ZMapp.
-Also while at DARPA, he launched Prophecy, the international physician Early Alert network, which delivers 24/7 emergency consultation, reagents and therapeutics for catastrophic (mass-casualty or HDP) infectious disease outbreaks, severe acute respiratory syndrome Hong Kong and H7N9 Nanjing.
-His drugs in market include Ambisome [[Gilead]], which has generated $6 billion since approval, cPG100, and four private-sector INDs involving novel anti-infectives, cytotherapeutics, or host-based antivirals. Dr. Callahan is president of [[United Therapeutics]] (UTHR) Division of Cell Therapeutics, and maintains faculty appointments at Massachusetts General Hospital/ [[Harvard Medical School]] and [[King Chulalongkom Medical University]] in Bangkok.
-Dr. Callahan continues his federal service as infectious disease and biosafety SME to the Academies, the [[National Security Council]], BSEG, the [[Office of Net Assessment]], National Institute of Allergy and Infectious Diseases, [[MITRE]], American Society of Microbiology, Infectious Disease Society of America, and the American Society of Tropical Medicine and Hygiene.((https://web.archive.org/web/20200803062045/https://www.ncbi.nlm.nih.gov/books/NBK373319/))
 === Rescue Medicine ===